Ibrutinib Provides Long-term Benefits for Patients With CLL
Ibrutinib provides long term survival benefits to patients with chronic lymphocytic leukemia regardless of cytogenetic risk factors.
ASCO 2017
Cediranib Prolongs Progression-free Survival in Alveolar Soft Part Sarcoma
Data suggest that cediranib-treatment of ASPS results in a substantial reduction in tumor burden and prolonged PFS.
Regorafenib Clinically Active in Ewing Sarcoma
SARC024 study met its primary endpoint for patients with Ewing sarcoma, and enrollment is ongoing for the liposarcoma and osteosarcoma cohorts.
Pazopanib Active in Malignant/Dedifferentiated SFT
Pazopanib showed antitumor efficacy among patients with unresectable or metastatic malignant/dedifferentiated soft fibrous tumors.
Adjuvant Capecitabine Prolongs Survival in Biliary Tract Cancer
Study results suggest that capecitabine should be incorporated into standard care for biliary tract cancer.
Affordable Care Act Increased Rate of Early Cancer Diagnoses
The US Affordable Care Act may have increased the proportion of patients with cancer diagnosed at stage I, according to a study.
Adjuvant Gefitinib Prolongs Disease-free Survival in Non-small Cell Lung Cancer
Adjuvant gefitinib significantly prolongs disease-free survival compared with vinorelbine plus cisplatin among patients with stage II to III non-small cell lung cancer.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2017
